PolyPid Ltd. (PYPD)
NASDAQ (CM) NASDAQ (CM) Primary 
XFRA 
PolyPid Nears FDA Decision for D-PLEX100 After Strong Phase III Data
PolyPid NASDAQ: PYPD is approaching a November 28 PDUFA date for D-PLEX100, its lead product candidate for preventing surgical site infections in patients undergoing colorectal surgery, Chief Executive Officer Dikla Czaczkes Akselbrad said during the Lytham Partners Fall 2026 Investor Conference.
PolyPid Q2 Earnings Call Highlights
PolyPid NASDAQ: PYPD said its second-quarter 2026 was marked by the FDA's acceptance of its new drug application for D-PLEX100 and a commercialization agreement with Azurity Pharmaceuticals covering the United States and Canada.
PolyPid Q1 Earnings Call Highlights
PolyPid NASDAQ: PYPD said its first quarter marked a transition from late-stage clinical development toward regulatory submission and commercial preparation for D-PLEX100, its lead product candidate for preventing surgical site infections in abdominal colorectal surgery.
PolyPid Ltd. (PYPD) Q1 2026 Earnings Call Transcript
PolyPid Ltd. (PYPD) Q1 2026 Earnings Call Transcript
PolyPid Ltd. (PYPD) Q4 2025 Earnings Call Transcript
PolyPid Ltd. (PYPD) Q4 2025 Earnings Call Transcript
PolyPid Ltd. (PYPD) Discusses the Science and Business Case for D-PLEX100 in Tackling Surgical Site Infections Transcript
PolyPid Ltd. (PYPD) Discusses the Science and Business Case for D-PLEX100 in Tackling Surgical Site Infections Transcript
PolyPid Ltd. (PYPD) Q2 2025 Earnings Call Transcript
PolyPid Ltd. (NASDAQ:PYPD ) Q2 2025 Earnings Conference Call August 13, 2025 8:30 AM ET Company Participants Dikla Czaczkes Akselbrad - CEO & Director Jonny Missulawin - Chief Financial Officer Ori Warshavsky - Chief Operating Officer—US Conference Call Participants Chase Richard Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Douglas Royal Buchanan - Citizens JMP Securities, LLC, Research Division Yehuda Leibler - Unidentified Company Operator Greetings, and welcome to PolyPid's Second Quarter 2025 Conference Call.
PolyPid Ltd. (PYPD) Q1 2025 Earnings Call Transcript
PolyPid Ltd. (NASDAQ:PYPD ) Q1 2025 Earnings Call May 14, 2025 8:30 AM ET Company Participants Brian Ritchie - Investor Relations Dikla Czaczkes Akselbrad - Chief Executive Officer Jonny Missulawin - Chief Financial Officer Ori Warshavsky - Chief Operating Officer, U.S. Conference Call Participants Roy Buchanan - JMP Securities Chase Knickerbocker - Craig-Hallum Bupalan Pachaiyappan - ROTH Capital Brian Ritchie Thank you all for participating in PolyPid's First Quarter 2025 Earnings Conference Call.
PolyPid Ltd. (PYPD) Q4 2024 Earnings Call Transcript
PolyPid Ltd. (NASDAQ:PYPD ) Q4 2024 Results Conference Call February 12, 2025 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors Dikla Czaczkes Akselbrad - Chief Executive Officer Jonny Missulawin - Chief Financial Officer Ori Warshavsky - Chief Operating Officer, U.S. Conference Call Participants Roy Buchanan - JMP Chase Knickerbocker - Craig-Hallum Ram Selvaraju - H.C.
PolyPid Ltd. (PYPD) Q3 2024 Earnings Call Transcript
PolyPid Ltd. (NASDAQ:PYPD ) Q3 2024 Earnings Conference Call November 13, 2024 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors Dikla Czaczkes Akselbrad - Chief Executive Officer Ori Warshavsky - Chief Operating Officer, U.S. Jonny Missulawin - Chief Financial Officer Conference Call Participants Roy Buchanan - JMP Chase Knickerbocker - Craig-Hallum Operator Greetings, and welcome to the PolyPid Third Quarter 2024 Conference Call.
PolyPid Ltd (PYPD) Q2 2024 Earnings Call Transcript
PolyPid Ltd (NASDAQ:PYPD ) Q2 2024 Results Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors Dikla Czaczkes Akselbrad - Chief Executive Officer Ori Warshavsky - Chief Operating Officer, US Jonny Missulawin - Chief Financial Officer Conference Call Participants Roy Buchanan - JMP Securities Raghuram Selvaraju - H.C. Wainwright & Co. Operator Greetings and welcome to the PolyPid Second Quarter 2024 Conference Call.
